Black diamond therapeutics investor relations
WebNov 18, 2024 · Black Diamond Therapeutics is not a large company by global standards. It has a market capitalization of US$276m, which means it wouldn't have the attention of many institutional investors. WebMar 9, 2024 · In April 2024, Black Diamond dosed the first patient in its Phase 1 global clinical trial of BDTX-1535 for the treatment of NSCLC, including in patients with brain metastases, and GBM. The dose-escalation portion of the Phase 1 clinical trial is actively recruiting and enrolling patients, and the Company remains on track to provide a clinical ...
Black diamond therapeutics investor relations
Did you know?
WebBlack Diamond Therapeutics has raised a total of $197.1M in funding over 4 rounds. Their latest funding was raised on Dec 5, 2024 from a Series C round. Black Diamond Therapeutics is registered under the ticker NASDAQ:BDTX . Their stock opened with $19.00 in its Jan 29, 2024 IPO. Black Diamond Therapeutics is funded by 16 investors. WebFind the latest Earnings Report Date for Black Diamond Therapeutics, Inc. Common Stock (BDTX) at Nasdaq.com.
WebApr 8, 2024 · In December 2024, Black Diamond Therapeutics had US$315m in cash, and was debt-free. Importantly, its cash burn was US$52m over the trailing twelve months. So it had a cash runway of about 6.0 ... WebFeb 27, 2024 · The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level …
WebNov 24, 2024 · CAMBRIDGE, Mass. and NEW YORK, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. … WebJan 10, 2024 · Black Diamond Therapeutics Closes $85 Million Series B Financing. CAMBRIDGE, Mass. and BASEL, Switzerland, Jan. 9, 2024 /PRNewswire/ -- Black …
WebDate March 3, 2024 Time 9:00 am MT (11:00 am ET) Dial-In 1-800-319-4610 1-604-638-5340 Webcast Recording
polltgluttWebFeb 27, 2024 · The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data and validate ... polluriskWebFeb 27, 2024 · Black Diamond Therapeutics, Inc. February 27, 2024, 8:00 AM · 2 min read. Black Diamond Therapeutics, Inc. CAMBRIDGE, Mass. and NEW YORK, NY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Black Diamond ... bank st hyundai ottawaWebMar 2, 2024 · March 02 2024. Black Diamond Group Limited Announces Fourth Quarter 2024 Results Conference Call. February 06 2024. Black Diamond Group Limited … polluant synonymeWebFeb 27, 2024 · About Black Diamond. Black Diamond Therapeutics is a clinical-stage precision oncology medicine company focused on the development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. ... Stern Investor Relations (212) 362-1200 [email protected] [email protected]. Site - Shareholder … polluentiWebSep 12, 2024 · Sep 12, 2024, 08:17 ET. CAMBRIDGE, Mass., Sept. 12, 2024 /PRNewswire/ -- Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small ... polluks i kastorWebJanuary 5, 2024 Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference All News » Follow us LinkedIn polls to take online